阿尔茨海默病在微质细胞中的遗传变异的功能性特征
Xiaoyu Yang1, Jia Wen2, Han Yang1
1Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA.
Nature genetics
|September 21, 2023
概括
微细胞候选 cis调节元件 (cCREs) 富含阿尔茨海默病 (AD) 遗传性. 这项研究确定了新的AD风险变体及其对微质中的基因表达和AD病理学的功能影响.
科学领域:
- 遗传学 遗传学 是一个
- 神经科学是一个神经科学.
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 的遗传性在微质候选 cis 调节元件 (cCREs) 中显著丰富.
- 全基因组关联研究 (GWAS) 变异在阿尔茨海默氏病变发生过程中的功能作用仍然在很大程度上是未知的.
- 了解细胞类型特定的遗传贡献对于阐明AD机制至关重要.
研究的目的:
- 优先考虑和功能性地描述微质cCREs内的新型AD风险变异.
- 建立特定遗传变异与它们在微质中的基因之间的联系.
- 研究AD相关变异对微质功能和AD病理学的生理后果.
主要方法:
- 将遗传数据与微质特异的3D表观基因组注释集成,以优先考虑AD风险变异.
- 在微质中选单细胞CRISPR干扰 (CRISPRi),以将功能变异与向基因联系起来.
- 基失衡分析,以评估AD变体对基因表达的影响.
- 功能性测试用于评估特定变体 (如rs7922621) 对蛋白质脱落和细胞表面表达的生理影响.
主要成果:
- 308个以前未报告的AD风险变异被优先考虑在181个cCREs使用遗传和表观遗传学数据.
- 单细胞CRISPRi查确定了微质内功能变异及其向基因.
- 阿尔茨海默病风险变体在基因表达中表现出基因失衡.
- 鉴定出 rs7922621 变种是 TSPAN14 表达的关键调节者,它影响了 ADAM10 和 TREM2 的分泌.
结论:
- 这项研究提供了一种系统的方法来优先考虑和描述微质中的AD相关变异.
- 这些发现将特定的遗传变异与改变的微质功能和AD病理联系起来.
- 这项工作为将遗传发现转化为经过实验验证的AD的细胞类型特定机制提供了路线图.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
Amyloid Fibrils
9.6K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.6K


